Zai Lab Stock Forecast, Price & News

-6.79 (-4.76 %)
(As of 07/29/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.43 million shs
Average Volume507,031 shs
Market Capitalization$12.89 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter.

Zai Lab logo

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops, and commercializes therapeutics to treat oncology, autoimmune, and infectious diseases in China. The company offers ZEJULA for the treatment of breast cancer and non-small cell lung cancer (NSCLC); and Optune, a cancer therapy to treat glioblastoma multiforme. It also develops QINLOCK for the treatment of gastrointestinal stromal tumors; Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Bemarituzumab for the treatment of gastric and gastroesophageal junction cancer; and Omadacycline to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Efgartigimod to reduce disease-causing immunoglobulin G (IgG) antibodies; Retifanlimab to treat microsatellite instability high endometrial cancer; ZL-2309 for the treatment of metastatic pancreatic cancer, metastatic colorectal cancer, and other advanced solid tumors; ZL-1201 to treat solid tumors and hematological malignancies; ZL-1102 for the treatment of psoriasis; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited has license and collaboration agreements with the GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; and argenx BV. The company was incorporated in 2013 and is headquartered in Shanghai, China.


Zai Lab (NASDAQ:ZLAB) Trading Down 5%
Zai Lab (NASDAQ:ZLAB) Trading Down 5%
July 29, 2021 |
ZLAB Sep 2021 200.000 call
ZLAB Sep 2021 200.000 call
July 28, 2021 |
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $116.00
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $116.00
July 28, 2021 |
Zai Lab (NASDAQ:ZLAB) Shares Gap Down to $131.48
Zai Lab (NASDAQ:ZLAB) Shares Gap Down to $131.48
July 27, 2021 |
Zai Lab Enters Oversold Territory (ZLAB)
Zai Lab Enters Oversold Territory (ZLAB)
July 26, 2021 |
Zai Lab (NASDAQ:ZLAB) Sees Large Volume Increase
Zai Lab (NASDAQ:ZLAB) Sees Large Volume Increase
July 26, 2021 |
ZLAB Aug 2021 175.000 call
ZLAB Aug 2021 175.000 call
July 23, 2021 |
Zai Lab (NASDAQ:ZLAB)  Shares Down 6.9%
Zai Lab (NASDAQ:ZLAB) Shares Down 6.9%
July 23, 2021 |
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.80 out of 5 stars

Medical Sector

548th out of 2,214 stocks

Pharmaceutical Preparations Industry

276th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

Is Zai Lab a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zai Lab stock.
View analyst ratings for Zai Lab
or view top-rated stocks.

What stocks does MarketBeat like better than Zai Lab?

Wall Street analysts have given Zai Lab a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zai Lab wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Zai Lab

How can I listen to Zai Lab's earnings call?

Zai Lab will be holding an earnings conference call on Tuesday, August 10th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zai Lab's earnings last quarter?

Zai Lab Limited (NASDAQ:ZLAB) announced its earnings results on Monday, May, 10th. The company reported ($2.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $1.78. The business had revenue of $20.10 million for the quarter, compared to analyst estimates of $19 million.
View Zai Lab's earnings history

How has Zai Lab's stock price been impacted by COVID-19 (Coronavirus)?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZLAB shares have increased by 171.0% and is now trading at $135.84.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZLAB?

5 Wall Street analysts have issued 12-month price targets for Zai Lab's stock. Their forecasts range from $111.00 to $250.00. On average, they anticipate Zai Lab's share price to reach $199.85 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts' price targets for Zai Lab
or view top-rated stocks among Wall Street analysts.

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Dr. Ying Du, Founder, Chairperson & CEO (Age 55, Pay $1.38M)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 43, Pay $624.96k)
  • Mr. Frazor Titus Edmondson III, Chief Legal Officer & Corp. Sec. (Age 55, Pay $707.3k)
  • Mr. Tao Fu, Chief Strategy Officer (Age 49, Pay $649.77k)
  • Dr. Alan Bart Sandler M.D., Pres & Head of Global Devel. in Oncology (Age 64, Pay $545k)
  • Ms. Ann Beasley, Chief Compliance Officer
  • Dr. Ning Xu M.D., Exec. VP & Head of Clinical Operations (Age 56)
  • Dr. Jonathan J. Wang M.B.A., Ph.D., MBA, Exec. VP & Head of Bus. Devel. (Age 39)
  • Dr. James Yan DABT, M.D., Ph.D., Chief Operating Officer of R&D (Age 57)
  • Dr. Harald Reinhart M.D., Chief Medical Officer of Autoimmune & Infectious Diseases (Age 69)

Who are some of Zai Lab's key competitors?

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN).

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Golden Green Inc. (0.00%) and DAVENPORT & Co LLC (0.00%). Company insiders that own Zai Lab stock include Harald Reinhart, John D Diekman, Kai-Xian Chen, Tao Fu, William Ki Chul Cho and Ying Du.
View institutional ownership trends for Zai Lab

Which major investors are buying Zai Lab stock?

ZLAB stock was bought by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, and Golden Green Inc..
View insider buying and selling activity for Zai Lab
or or view top insider-buying stocks.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $135.84.

How much money does Zai Lab make?

Zai Lab has a market capitalization of $12.89 billion and generates $48.96 million in revenue each year. The company earns $-268,900,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Zai Lab have?

Zai Lab employs 1,194 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is

Where are Zai Lab's headquarters?

Zai Lab is headquartered at 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.